Infectious Diseases News and Research

RSS

Microsoft launches a new online H1N1 Flu Response Center

With the current H1N1 flu (swine flu) pandemic under way, many public health officials are concerned that critical healthcare resources could be stretched thin as people flood hospital emergency departments and physicians' offices to determine whether they have the illness.

7 Oct 2009

Galapagos receives EUR 500,000 cash payment from GSK

Galapagos NV (Euronext: GLPG) announced today that it has reached the first milestone in its antibacterials and antivirals alliance with GlaxoSmithKline (GSK). For achieving this milestone, Galapagos receives a EUR 500,000 cash payment from GSK.

7 Oct 2009

Gen-Probe to acquire Prodesse for $60 million in cash

Gen-Probe Incorporated announced today that it has signed a definitive agreement to acquire Prodesse, Inc., a privately held leader in molecular testing for influenza and other infectious diseases, for approximately $60 million in cash. Gen-Probe's purchase price could increase to up to $85 million if Prodesse achieves certain financial and regulatory milestones in 2010 and 2011.

7 Oct 2009

Parents should watch out for flu warning signs, says Minnesota physicians

Minnesota's physicians are urging parents to watch for the warning signs that their child is having a severe case of H1N1 and to seek out the H1N1 vaccine for their child when it becomes available.

7 Oct 2009

Research to explore diagnosis and treatment of rare diseases

The National Institutes of Health announced today a second phase of the Rare Diseases Clinical Research Network (RDCRN) including funds for 19 research consortia.

7 Oct 2009

New study leads to the development of first prophylactic treatment for leishmania

Leishmania is a deadly parasitic disease that affects over 12 million people worldwide, with more than 2 million new cases reported every year. Until recently, scientists were unsure exactly how the parasite survives inside human cells. That mystery has now been solved according to a new study published in Science Signaling by a team led by Dr. Martin Olivier - a scientist at the Research Institute of the McGill University Health Centre (RI-MUHC) and McGill University.

7 Oct 2009

Measures taken by Memorial Blood Centers to stay prepared for the spread of H1N1 virus

Memorial Blood Centers today outlined steps the organization is taking to stay prepared for the spread of the H1N1 virus and to ensure a safe experience for blood donors and an ample blood supply for our communities.

7 Oct 2009

Researchers make breakthrough in finding a vaccine against horse disease strangle

A research group at the Department of Microbiology, Swedish University of Agricultural Sciences (SLU) in Uppsala, Sweden has - in collaboration with J-I Flock's research group at the Karolinska Institutet medical university in Stockholm, the pharmacological company Intervacc AB, Stockholm and the Animal Health Trust in the UK - after many years of research made a breakthrough in finding a vaccine against the horse disease strangle.

7 Oct 2009

PDS Biotechnology's Versamune-based immunotherapy drug demonstrates safety in preclinical studies

PDS Biotechnology Corporation today announced that the company has completed GLP toxicology studies of its lead HPV-cancer product. The studies, which included pharmacokinetic (PK) and adsorption, bio-distribution and excretion (ADE) studies in addition to the evaluation of toxicity, all demonstrated a very safe profile of the drug and PDS Biotech's platform Versamune((TM)) technology.

6 Oct 2009

Ground Zero Pharmaceuticals opens new office in Brisbane

A major increase in innovative concepts for exciting therapeutic and preventive new products in Australia has led to an expansion of GZP's activities Down Under, to better support clients in their efforts to take their programs to the US Food and Drug Administration.

6 Oct 2009

NIAID's grant to VBI for biomedical research on infectious diseases

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded a five-year, $27,670,448 contract to the CyberInfrastructure Group (CIG) of the Virginia Bioinformatics Institute (VBI) at Virginia Tech to support the biomedical research community's work on infectious diseases.

6 Oct 2009

Inviragen, SingVax merge their complementary vaccine pipelines

Inviragen and SingVax have merged their complementary vaccine pipelines and their international product development capabilities to create a company that is developing a wide range of vaccines for infectious diseases prevalent in emerging economies.

6 Oct 2009

Majority of Europeans not concerned about H1N1

Three quarters of European people surveyed between the 30th April and 6th May 2009 said they were either not at all concerned or only a little concerned about swine flu.

6 Oct 2009

Sequella receives ARRA funds to manufacture SQ109 for treating tuberculosis

Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing novel antibiotics to treat life-threatening infectious diseases, today announced that it received a $694,000 grant supplement as part of the American Recovery and Reinvestment Act (ARRA) of 2009.

6 Oct 2009

High mortality rates may play a role in the evolution of human body size

A new study suggests that high mortality rates in small-bodied people, commonly known as pygmies, may be part of the reason for their small stature. The study, by Jay Stock and Andrea Migliano, both of the University of Cambridge, helps unravel the mystery of how small-bodied people got that way.

6 Oct 2009

News outlets examines health impact of disasters in Indonesia, Samoa, Philippines

In Indonesia, "[r]escue workers called off the search Monday for life under the rubble left by a massive earthquake, focusing instead on bringing aid to survivors," the Agence France-Presse reports. "The United Nations has said at least 1,100 people were killed in the disaster, but estimates of the final toll range up to 5,000. The official toll stood at 650 dead and 672 missing, according to the health ministry," the news service writes (Belford, 10/5).

6 Oct 2009

AVI BioPharma receives $11.5M DTRA fund to develop AVI-7012 for treating Junin virus infection

AVI BioPharma, Inc. a developer of RNA-based drugs, announced today that it has received expanded contract funding of approximately $11.5 million from the Defense Threat Reduction Agency's (DTRA) Transformational Medical Technologies Initiative (TMTI) to support development of the Investigational New Drug (IND) data package for its candidate drug, AVI-7012, to treat Junin virus infection.

5 Oct 2009

Misuse of aspirin might have caused high death rate during 1918-1919 influenza pandemic

The devastation of the 1918-1919 influenza pandemic is well known, but a new article suggests a surprising factor in the high death toll: the misuse of aspirin. Appearing in the November 1 issue of Clinical Infectious Diseases and available online now, the article sounds a cautionary note as present day concerns about the novel H1N1 virus run high.

3 Oct 2009

Surgical masks appear as effective as N95 respirators against influenza: Study

A McMaster University study has found that surgical masks appear to be as good as N95 respirators in protecting health-care workers against influenza.

3 Oct 2009

JBAIDS approved by the military for H1N1 virus detection tests

Idaho Technology’s Joint Biological Agent Identification and Diagnostic System (JBAIDS) has been approved by the military to run tests for the H1N1 virus. Deployed across the globe, including in Iraq and Afghanistan, by all four branches of the military, the JBAIDS instrument will be used to test military personnel and their families for Influenza A, swine flu A and H1 swine flu in less than an hour.

3 Oct 2009